Trials / Completed
CompletedNCT04879953
Effect of the PIPAC on the Survival Rate of Patients With Peritoneal Carcinomatosis of Gastric Origin
Effect of Pressurised Intraperitoneal Aerosol Chemotherapy on the Survival Rate of Patients With Peritoneal Carcinomatosis of Gastric Origin
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 46 (actual)
- Sponsor
- Association Francaise de Chirurgie · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Pressurised intraperitoneal aerosol chemotherapy is a new surgical technique, developed for the treatment of initially unresectable peritoneal carcinomatosis. The objective of this study was to compare the results of PIPAC associated with systemic chemotherapy with those of systemic chemotherapy alone in patients with gastric peritoneal carcinomatosis without metastasis other than peritoneal, and WHO performance status \<3.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PIPAC with systemic chemotherapy | PIPAC procedures were performed every 6 to 8 weeks, alternating with systemic chemotherapy, replacing a cycle of intravenous chemotherapy. |
| DRUG | Systemic chemotherapy alone | Intravenous chemotherapy |
Timeline
- Start date
- 2020-02-01
- Primary completion
- 2020-08-30
- Completion
- 2020-12-31
- First posted
- 2021-05-10
- Last updated
- 2021-05-11
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04879953. Inclusion in this directory is not an endorsement.